Navigation Links
Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
Date:2/5/2008

06. Total operating expenses for the fourth quarter of 2007 were $10.4 million, compared to $12.0 million for the same period in 2006.

Net interest and other income was $935,000 for the fourth quarter of 2007, compared to $858,000 for the same period in 2006, primarily due to higher average cash and investment balances.

Full Year Results

For the year ended December 31, 2007, the consolidated net loss was $21.5 million, or $0.58 per share, compared to a net loss of $17.9 million, or $0.55 per share, for the year ended December 31, 2006. Revenues were $9.1 million for 2007, compared to $7.9 million in 2006. Total operating expenses were $33.9 million in 2007 and $28.6 million in 2006. Operating expenses in 2006 included the acquisition of the Edwards Lifesciences' ZFP Therapeutic angiogenesis program, a one-time cost for Sangamo of $5.8 million. The increase in operating expenses for 2007 was primarily associated with Sangamo's clinical development program in diabetic neuropathy and pre-IND programs to develop ZFP Therapeutics for the treatment of HIV/AIDS and glioblastoma, as well as increased R & D personnel costs and lab supply expenses.

2007 Highlights

-- Presentation of first clinical data from Phase 1b study of SB-509 in

subjects with diabetic neuropathy (DN). Data from the Phase 1b

clinical trial were presented at the American Diabetes Association

Meeting in June and the Society for Neuroscience Meeting in November.

The data demonstrate statistically significant improvement in

quantitative sensory testing and clinically relevant trends toward

improvement in nerve conduction velocity in subjects with mild to

moderate diabetic neuropathy over a six month period after a single

administration of SB-509. SB-509 is an injectable formulation of

plasmid DNA that encodes a zinc finger DNA-binding protein

transcription factor (ZFP
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
2. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
3. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
4. CeloNova BioSciences Introduces a New Class of Coronary Stent: The CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F
5. CeloNova BioSciences Announces Positive Results from European Study of Embozene(TM) Microspheres for Treatment of Uterine Fibroids
6. Epiphany Biosciences Reports Initiation of Phase 2 Study of Valomaciclovir for the Treatment of Acute Infectious Mononucleosis
7. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
8. Epiphany Biosciences Reports Initiation and Enrollment in Valomaciclovir Study for Shingles
9. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
10. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
11. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2013)... The Partnership at Drugfree.org , in ... the fourth annual Commissioner,s Play Healthy Awards ... the playing field. The awards are an extension of ... website, to educate families on the risks of ... and student athletes who embody the spirit of teamwork ...
(Date:6/20/2013)... Colo. , June 20, 2013 Sirtex ... today announced a sales and marketing partnership to distribute ... the interventional radiology and oncology markets. The agreement ... products in the company,s rapidly growing Asia Pacific ... Sirtex reported a 30 per cent growth in dose ...
(Date:6/20/2013)... 2013 Today Moscamed made the first ... a new programme to control the dengue mosquito Aedes ... of Bahia. In previous trials Moscamed have demonstrated ... reduce the number of dengue mosquitoes in a town. In ... mosquitoes were reduced by 96% within 6 months and it ...
Breaking Medicine Technology:Major League Baseball Charities and The Partnership at Drugfree.org Announce the Fourth Annual Commissioner's Play Healthy Awards 2Major League Baseball Charities and The Partnership at Drugfree.org Announce the Fourth Annual Commissioner's Play Healthy Awards 3Major League Baseball Charities and The Partnership at Drugfree.org Announce the Fourth Annual Commissioner's Play Healthy Awards 4Sirtex To Distribute Surefire Medical's Innovative Infusion System in Australia and Asia Pacific Markets 2Moscamed Launches Urban Scale Project Using Oxitec GM Mosquitoes in Battle Against Dengue 2Moscamed Launches Urban Scale Project Using Oxitec GM Mosquitoes in Battle Against Dengue 3
... -- Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: ... in the development, manufacturing, and marketing of branded and ... Mr. Hong Zhao, a highly regarded executive in the ... sales and marketing, effective February 12, 2011. ...
... Calif., Feb. 10, 2011 Renaissance Surgical Arts at Newport ... center in the Western United States to offer intraoperative radiotherapy ... in the TARGIT-A multicenter human clinical trial that demonstrated IORT ... with early breast cancer. IORT has the ...
Cached Medicine Technology:Simcere Pharmaceutical Group Appoints Industry Veteran Mr. Hong Zhao as Executive Vice President of Sales and Marketing 2Renaissance Surgical Arts at Newport Harbor Announces Single-Dose Radiation Treatment Alternative for Women with Early Breast Cancer 2Renaissance Surgical Arts at Newport Harbor Announces Single-Dose Radiation Treatment Alternative for Women with Early Breast Cancer 3
(Date:6/20/2013)... June 20, 2013 This ... focuses mainly on the oral and injectable ... report enumerates the various formulation technologies involved ... and advantages of specific technologies. Wherever possible, ... been discussed as proof of validation along ...
(Date:6/20/2013)... Beverly Hills, CA (PRWEB) June 20, 2013 ... David M. Amron, has been named by The Patient’s ... as an expert in liposuction, Dr. Amron will now ... Patient’s Guide. The Patient's Guide sees over one million ... provides information and articles related to plastic surgery and ...
(Date:6/20/2013)... Novatus Contract Management , the ... next release of upgrades and enhancements will be available ... system more robust, but continue to add investment value ... Online Negotiation Portal™ Interface enhancements – ... Portal from the outside. , Company Relationships ...
(Date:6/20/2013)... 20, 2013 Presenting at the ... society president and keynote speaker Dr. Rod ... future of rhinoplasty (plastic surgery of the nose) ... from across the nation. In his address, Dr. ... rhinoplasty to current open-technique rhinoplasty that reduces risk ...
(Date:6/20/2013)... weight may not reverse the damage that has been done ... even moderate weight loss can have a dramatic effect on ... within normal and healthy weight ranges is ideal, starting with ... shown to help relieve joint pain, as well as help ... have revealed that a weight loss of 11 pounds decreases ...
Breaking Medicine News(10 mins):Health News:Novel Drug Delivery Systems Market (NDDS): Formulations (Oral & Injectable) Analysis in Research Report at RnRMarketResearch.com 2Health News:Novel Drug Delivery Systems Market (NDDS): Formulations (Oral & Injectable) Analysis in Research Report at RnRMarketResearch.com 3Health News:Novel Drug Delivery Systems Market (NDDS): Formulations (Oral & Injectable) Analysis in Research Report at RnRMarketResearch.com 4Health News:Liposuction Guru, Dr. David Amron, Receives Award From The Patient’s Guide 2Health News:Novatus Contract Management Newest Enhancements and Upgrades to be Available July 1 2Health News:Dr. Rod J. Rohrich Delivers Keynote Address on the Future of Rhinoplasty 2Health News:Dr. Rod J. Rohrich Delivers Keynote Address on the Future of Rhinoplasty 3Health News:Dr. Rod J. Rohrich Delivers Keynote Address on the Future of Rhinoplasty 4Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Offers New Diet Plans, Now Capable of Helping Patient’s Avoid The Risk of Arthritis With Natural Weight Loss 2Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Offers New Diet Plans, Now Capable of Helping Patient’s Avoid The Risk of Arthritis With Natural Weight Loss 3
... SPRING, Md., Feb. 28 Celebrity chef Emeril,Lagasse joins ... top,quality food with viewers this summer in the new ... 24/7 eco-lifestyle,television network, is set to launch in June ... premiering throughout the summer, including,EMERIL GREEN (wt) which will ...
... TDP-43 mutations expose potential therapeutic target, experts say , , ... a new, yet rare, genetic mutation in the development ... only exposes a potential therapeutic target for treating the ... mutation sets in motion the mechanism that causes many ...
... and men are completely satisfied with the time they spend ... study published in the Journal of Family Issues. , ... be more time pressured than those who work part time ... professor of sociology at Kent State University. , In ...
... will Integrate IDC,s X1590 into the First Standardized ... ... /PRNewswire-FirstCall/ - IDC (Imaging Dynamics Company,Ltd.) (TSX: IDL), the global ... announced that Halifax Biomedical has selected,IDC,s X1590 as the DR ...
... PRINCETON, N.J., Feb. 28 Organizations,representing the state,s ... funding cuts proposed for hospital care for New ... $33 billion state spending plan for 2009, released,Tuesday, ... with funding of $608,million compared with current funding ...
... unlocked some of the mysteries of how the developing ... A present in the maternal blood stream. Their results ... Journal of Biological Chemistry. , The researchers studied ... formation of vitamin A stores in the body, during ...
Cached Medicine News:Health News:Emeril Lagasse and Planet Green Partner with Whole Foods Market(R) on Innovative New Series 2Health News:Emeril Lagasse and Planet Green Partner with Whole Foods Market(R) on Innovative New Series 3Health News:New Gene for Lou Gehrig's Disease Identified 2Health News:New Gene for Lou Gehrig's Disease Identified 3Health News:IDC X-Series DR system selected for use in leading edge RSA clinical trial application 2Health News:IDC X-Series DR system selected for use in leading edge RSA clinical trial application 3Health News:Hospital Groups United in Opposition to Charity Care Cuts 2Health News:Rutgers researchers unlock mysteries of vitamin A metabolism during embryonic development 2Health News:Rutgers researchers unlock mysteries of vitamin A metabolism during embryonic development 3